Introduction
On 29 and 30 September 2011 the WHO Collaborating Centre (WHO CC) for Pharmaceutical Pricing and Reimbursement Policies organized the second PPRI Conference in Vienna, Austria. This was attended by 275 delegates (offi cials and staff of public authorities and payers, pharmaceutical companies, researchers) from 56 countries, and included 60 speakers, panelists and chairs. It addressed pharmaceutical policies from a public health perspective, from both a European and global context. [1] [2] [3] . The fi rst PPRI Conference focused on European pricing and reimbursement policies [4] , but generics policies were not a key topic at the conference. Just one presentation, by Professor Richard Laing from WHO, about availability, affordability and price components of medicines in developing and transitional countries [5] , highlighting price differences between originators and generic medicines assessed according to WHO/HAI (Health Action International) methodology [6, 7] , addressed the generics policy.
The second PPRI Conference was organized in response to requests from participants at the previous conference for a follow-up, and was an activity under the terms of reference of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (established in June 2011). The conference objective was to provide information about the activities and the results of the PPRI and Pharmaceutical Health Information System (PHIS) projects. The PPRI initiative has continued as a voluntary networking and information sharing initiative of competent authorities for pricing and reimbursement after the PPRI project offi cially ended in 2008. The PHIS project (September 2008 to April 2011) [8] was based on the lessons learned and looked particularly at medicines management in the inpatient sector, for which scant literature existed. As a result, the PHIS project called for an urgent improvement in cooperation at the interface between outpatient and hospital sectors [9] .
The second PPRI Conference therefore had a focus on 'hospital pharma and interface management' and contained three parallel strands: (1) pricing and reimbursement, (2) rational use of medicines and (3) hospital pharma and interface management. The majority of the participants (more than 50 per cent) attended the strand on 'pricing and reimbursement'. The topics of generics and generics policies appeared in all three strands.
Panelists and speakers in the plenary sessions
Generics were mentioned in 48 (64%) of the total of 75 contributions (presentations, posters, panel discussions), and in 22 of 48 accepted abstracts (46%). During the fi rst high-level panel discussion Mr Kees de Joncheere, then Regional Adviser for Health Technology and Pharmaceuticals for WHO Europe (now Head of the Essential Medicines Department in WHO Headquarters), stressed the great potential of generics policies and the need to apply these more frequently. Mr Richard Bergstrom, President of the European Federation of Pharmaceutical Industries and Associations (EFPIA), stated that 'once patents expire, prices should fall to a low, but sustainable, level'. In this panel discussion but also throughout the conference there appeared to be a common understanding that generics competition works well. Dr Andreas Seiter (World Bank) [10] , expressed concern about having a pricing regulation policy that fi xes a difference between the originator and the generic(s) (so-called 'generic price link', [11] ) because this could impede further benefi ts and savings that could be achieved through full generics competition.
Country case studies
Presentations and posters described the pharmaceutical situation in 37 different countries, including generics policies and their outcomes. In Croatia, for instance, a generic price link and [11, 16] . This situation had been criticized as a lost opportunity for savings [17, 18] . Portugal was the only country of the EU to have higher generics market shares in value than in volume [1] , which is an indicator of a high price level of generic medicines. A change in methodology in 2010 led to the reference price being redefi ned as the average of the fi ve cheapest generics [19] . Dr Gomes presented data on how the generics market had developed well, from a starting point of 3.5% in volume in 2003 to a break-even point in 2010 at which generics shares became lower in value than in volume, see Figure 1 . Additional data on the development of the average generics prices confi rmed a reduction in prices of generic medicines from the fi rst months of 2010 onwards [15] . Generics policies therefore need to be designed for maximum potential benefi t.
Case studies of enhancing generics uptake
Some European countries reported about differences in price between original products and generic medicines, for example, regarding generic omeprazole and simvastatin ( [20] , see also the article [21] ) generic ACE (angiotensin-converting-enzyme) inhibitors and SSRI's (selective serotonin re-uptake inhibitors). Dr Kristina Garuoliene, from the Lithuanian National Health Insurance Fund demonstrated how her country, with its small population, was able to achieve considerable price reductions for generic versus originator medicines, see Table 1 [22] . Dr Kristina Garuoliene also presented a case study of clopidogrel and described how public authorities and payers were concerned about how differences in the salt composi-tion, and indications, between originator and generic clopidogrel could potentially reduce savings from generics availability. Responding to efforts by the originator company to retain sales, authorities adopted 'pragmatic approaches' to enhance generics prescribing, e.g. mandatory generic substitution, educational activities, see Table 2 [23, 24] . Still, the differences in the reimbursed prices of generic clopidogrel versus the originator were high across Europe, especially briefl y after launch, but decreasing over time.
In Abu Dhabi, a new policy for generic medicines, including compulsory International Non-proprietary Name prescribing, was introduced in 2009. However, the expected savings did not fully materialize Authorities wrote public letters stating no difference between generic and originator drug, in response to cardiologists' concerns. Activities to enhance generics prescribing include no prescribing restrictions, fi nancial incentives to physicians and regular publications.
Croatia 2006
Reference pricing based on the lowest priced molecules encourage prescribing of generics versus originator.
Germany 2008
Differences in salts and indications were dismissed by physicians, aided by educational inputs such as letters and articles.
Other generic clopidogrel-enhancing activities include rebate negotiations and fi nancial incentives.
Lithuania 2009
Acceptance of mandatory INN prescribing for clopidogrel. Community pharmacists obliged to stock cheapest generics to force down prices (already leading to a reduction in originator prices).
Scotland 2009
A pragmatic approach with area Drugs and Therapeutics Committees recommending prescribing of generics aided by high INN prescribing and low prices for generics (with market forces).
Delaying tactics
Norway 2010 Generic clopidogrel reimbursed in January 2010. However, patent and indications were challenged leading to removal in October 2010. Accepted again in March 2011 with extended indications.
Portugal 2009
First generics approved in April 2009 and reimbursed in December 2009. Some generics formulations later withdrawn due to manufacturing concerns. However, others withdrawn following lawsuits by originator leading to temporary suspension (12 formulations to date). since there were no accompanying measures to support an increased generics uptake. Abu Dhadi is now exploring a policy of introducing demand-side measures, including educational activities and the introduction of a reference price system for medicines grouped together if they had the same active ingredients [25] . [26] . The PPRI Conference confi rmed that in order to achieve the best possible benefi ts from generics policies, they have to be carefully designed and implemented in a consistent way. This is an original report from the PPRI Conference. Conference presentations, abstracts and posters are publicly accessible online at //whocc.goeg.at/Conference2011/ Programme
GaBI (Generics and Biosimilars Initiative) at the 'Meet the Editors' session

For patients
The PPRI Conference offered several good practice examples as well as a few less successful stories about the implementation of generics policies. Such sharing of information is crucial for policy-makers to know the impact of generics policies.
Well-informed policy-makers can contribute more effectively towards improving the accessibility of medicines, e.g. by applying generics policies in a consistent way and thus creating opportunities for innovation.
A further conclusion from the conference was that the perspectives of consumers and patients should be taken into account. Participants were reminded that pharmaceutical policies should benefi t all citizens, especially vulnerable groups, and that their perspectives should be actively considered.
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